UNSPSC 51312304: Diphenhydramine

This classification denotes a histamine-1 receptor antagonist and antiemetic agent with the molecular formula C17H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8GTS82S83M, chemically known as 2-(diphenylmethoxy)-n,n-dimethylethylamine hydrochloride but generally known as diphenhydramine, which bears US NIH Compound Identifier 3100. European Medicines Agency schedules Diphenhydramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07211MIG.

UNSPSC 51312304 Diphenhydramine is a Commodity code covering individual pharmaceutical products that state and local governments procure through health departments, county health systems, and cooperative purchasing alliances for community health initiatives, emergency response programs, and institutional pharmacy supply. Based on recent solicitations, the code sees activity centered on antihistamine medications and related pharmaceutical procurement, though the recent opportunities block shows limited direct diphenhydramine-specific buys; instead, state and local buyers are aggregating purchases of broader pharmaceutical categories—generic multi-source drugs and OTC products—through cooperative purchasing vehicles and health department channels. Issuing bodies include state health and human services departments, county health systems, and regional cooperative purchasing alliances. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, manages a major multi-state pharmaceutical procurement spanning participating state and local government facilities including Oregon; Seminole County, Florida's health department conducts direct pharmaceutical buys for community health initiatives; and the Texas Health and Human Services Commission uses RFI mechanisms to explore direct-to-manufacturer pharmacy programs.

Geographic activity concentrates in Minnesota, Florida, and Texas, with cooperative purchasing extending across multiple states through MMCAP participation. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the Minnesota Multistate Cooperative Purchasing Alliance RFP S1070000015802 (posted January 20, 2026, responses due March 26, 2026) for generic multi-source pharmaceuticals and OTC products with awards effective July 1, 2026 through authorized wholesalers AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson; and the Texas Health and Human Services Commission RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager arrangements. Vendors responding to pharmaceutical procurements under this code must comply with FDA requirements, cGMP and Drug Supply Chain Security Act certifications, E-Verify employment eligibility verification, drug-free workplace certification, and maintain significant liability insurance coverage.